Is Found a Good Fit for Transfer Patients? Plans & Costs Examined

Last reviewed: September 4, 2026 Last updated: September 4, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

PlexusDx publishes this comparison and is one of the providers discussed. We use the same evidence rules for our own program and competing programs.

The short answer

Found is a strong fit for transfer patients with qualifying insurance—its $199/month ongoing insurance rate (plus any copays) and in-network status for roughly one-third of Americans make it cost-effective when coverage applies. For cash-paying transfer patients, PlexusDx delivers lower ongoing costs: $189/month for semaglutide injection and $289/month for tirzepatide injection on standard monthly plans, with six-month rates dropping to $149 and $249 respectively. Found bills every four weeks (13 charges annually), while PlexusDx bills calendar monthly (12 charges). Transfer patients prioritizing format flexibility gain access to oral semaglutide, oral tirzepatide, and microdose maintenance protocols through PlexusDx; Found provides injectable semaglutide and tirzepatide only. Both platforms allow cancellation at any time, though Found explicitly offers a full refund if you're not clinically eligible—a useful safeguard when switching providers.

At-a-glance comparison

Found pricing captured September 4, 2026 from joinFound.com and PlexusDx comparison page. PlexusDx pricing captured September 4, 2026. Insurance rates may require copays; verify coverage at checkout.

Twelve-month cost comparison: like-for-like analysis

Transfer patients planning twelve months of continued treatment face meaningfully different cost structures depending on billing cadence and term commitment. The calculations below use standard ongoing monthly rates and prepaid totals only, verified at the dates shown.

Semaglutide injection: month-to-month plans

Found cash: $289 billed every four weeks produces thirteen charges per year. Twelve-month total: $3,757. True monthly average: $313.08 (our calculation).

PlexusDx: $189 billed calendar monthly produces twelve charges per year. Twelve-month total: $2,268. Average: $189/month.

Cost difference (MTM): PlexusDx costs $1,489 less annually than Found's cash month-to-month rate for semaglutide injection.

Semaglutide injection: longest available terms

Found cash (12-month prepaid): $2,028 total, billed once every 48 weeks. Per-month equivalent when prepaid: $169/month.

PlexusDx (6-month rate): $149/month over six months equals $894 per period. Two six-month periods: $1,788 annually (our calculation). Average: $149/month.

Cost difference (longest terms): PlexusDx six-month rate costs $240 less annually than Found's twelve-month prepaid rate for semaglutide injection.

Tirzepatide injection: month-to-month plans

Found cash: $359 every four weeks × 13 charges = $4,667 annually. True monthly average: $388.92 (our calculation).

PlexusDx: $289 calendar monthly × 12 charges = $3,468 annually. Average: $289/month.

Cost difference (MTM): PlexusDx costs $1,199 less annually than Found's cash month-to-month rate for tirzepatide injection.

Tirzepatide injection: longest available terms

Found cash (12-month prepaid): $2,868 total, billed once every 48 weeks. Per-month equivalent when prepaid: $239/month.

PlexusDx (6-month rate): $249/month over six months equals $1,494 per period. Two six-month periods: $2,988 annually (our calculation). Average: $249/month.

Cost difference (longest terms): Found's twelve-month prepaid tirzepatide rate costs $120 less annually than PlexusDx's six-month rate.

Found insurance track

Found advertises a $199/month ongoing rate with insurance, plus any applicable copays for provider visits. Insurance plans may cover part or all of the medication cost, though Found's compounded medications are included in the monthly fee. Over twelve months, the base subscription cost is $2,388 (12 charges at $199/month) before copays. Transfer patients with qualifying insurance should verify in-network status, copay amounts, and total out-of-pocket cost at enrollment.

Decision factors for transfer patients

Insurance coverage: Found's primary advantage

Found accepts most major insurance providers and reports in-network clinician access for approximately one in three Americans. Transfer patients with qualifying insurance pay a $199/month ongoing subscription rate plus any applicable copays. This structure can deliver meaningful savings compared to cash-pay options—provided your insurance plan covers visits and you confirm in-network status before enrolling. Found's insurance track also includes branded GLP-1 medications (billed separately), though compounded medications are included in the subscription cost.

Cash pricing: PlexusDx's structural advantage

For transfer patients paying cash, PlexusDx's month-to-month rates ($189 semaglutide, $289 tirzepatide) cost less than Found's cash month-to-month rates ($289 semaglutide, $359 tirzepatide). The difference compounds: Found bills every four weeks (thirteen charges annually), while PlexusDx bills calendar monthly (twelve charges). Over twelve months on month-to-month plans, PlexusDx costs $1,489 less for semaglutide and $1,199 less for tirzepatide (our calculations). PlexusDx's six-month rates ($149 semaglutide, $249 tirzepatide) maintain the cost advantage in most scenarios, though Found's twelve-month prepaid tirzepatide rate ($239/month equivalent) edges below PlexusDx's six-month tirzepatide rate by $120 annually.

Medication format flexibility

Found provides injectable semaglutide and tirzepatide only. Transfer patients seeking to switch from injections to oral administration, or exploring microdose maintenance protocols after reaching goal weight, cannot access those formats through Found. PlexusDx offers oral semaglutide ($289 MTM, $249 six-month), oral tirzepatide ($349 MTM, $279 six-month), and a microdose GLP-1 maintenance protocol ($129 MTM)—all with the same dose-invariant pricing structure. Transfer patients who experienced injection-site reactions, travel frequently, or prefer discretion often prioritize format flexibility.

Billing predictability and budgeting

Found's four-week billing cycle produces thirteen charges per calendar year, which can complicate annual budgeting and expense tracking. PlexusDx's calendar-month billing aligns with typical payroll and budgeting cycles. For transfer patients planning long-term use, the difference between twelve predictable charges and thirteen offset charges may influence cash-flow management, particularly when coordinating with HSA/FSA reimbursement schedules. Both platforms accept HSA/FSA payment, though Found explicitly advertises this feature while PlexusDx supports it operationally.

Included services and support model

Found bundles 24/7 app access, a care team, healthy habits guidance, and Aimee (an AI weight loss and lifestyle concierge) into its subscription. Transfer patients accustomed to ongoing coaching, frequent check-ins, or structured habit guidance may value this model. PlexusDx includes a free Doctor of Pharmacy check-in and offers an optional genetic testing add-on ($99 for program members, $298 standalone) to identify genetic factors influencing GLP-1 response. Transfer patients prioritizing clinical consultations over lifestyle coaching should evaluate which support structure better matches their established routine.

Cancellation and refund policies

Both platforms allow cancellation at any time. Found explicitly offers a full refund if you are not clinically eligible—a transfer-relevant safeguard when switching providers and facing uncertainty about formulary differences or medical history review. PlexusDx allows cancellation without a stated ineligibility refund policy. Transfer patients concerned about eligibility disruptions during the switch may find Found's explicit refund commitment reassuring.

Choose Found if…

You have qualifying insurance with in-network Found clinicians. The $199/month ongoing insurance rate (plus copays) typically costs less than cash alternatives when coverage applies, and access to branded medications (billed separately) may suit patients with insurance-reimbursed formularies. Transfer patients who rely on structured coaching, 24/7 app-based support, and AI-assisted habit guidance will find Found's bundled services aligned with an intensive support model. If your current provider does not accept your insurance and you meet Found's clinical criteria, the insurance pathway represents a meaningful cost reduction—confirm in-network status and copay amounts before enrolling.

Choose PlexusDx if…

You are paying cash and prioritize lower ongoing costs with billing predictability. Month-to-month rates ($189 semaglutide injection, $289 tirzepatide injection) cost less than Found's cash rates, and calendar-month billing produces twelve annual charges instead of thirteen. Transfer patients seeking format flexibility—oral capsules to avoid injections, or microdose protocols for maintenance after goal-weight achievement—gain access to options Found does not provide. If you value dose-invariant pricing (the same monthly cost at every dose level), a streamlined support model with optional pharmacist consultations, and the ability to switch between injectable, oral, and microdose formats without changing providers, PlexusDx delivers operational simplicity at a lower cash price point.

Methodology and freshness

All pricing data were captured September 4, 2026 from Found's public website (joinFound.com) and the PlexusDx comparison page. Twelve-month cost calculations are our calculations, derived from the stated billing cadences and monthly rates. Found's every-four-week billing produces thirteen charges annually; PlexusDx's calendar-month billing produces twelve charges annually. Insurance rates reflect advertised ongoing monthly charges; actual out-of-pocket costs depend on individual plan coverage, copays, and in-network status. We verified inclusions, format availability, and cancellation policies from each provider's current public materials. Prepaid totals reflect the full amount charged at each billing interval. Where sources stated per-month equivalents for prepaid plans, we labeled those figures as prepaid and calculated twelve-month totals independently.

Frequently Asked Questions

Can I transfer to Found or PlexusDx if I'm currently on a GLP-1 from another provider?

Yes, both Found and PlexusDx accept transfer patients already using GLP-1 medications. You will complete a medical intake, and a licensed provider reviews your history—including current dose, duration, and response—to determine whether continuing treatment is appropriate. Found offers a full refund if you are not clinically eligible after this review, which provides a safeguard during the transition.

Does Found's insurance track cover the medication cost, or just the subscription?

Found's $199/month ongoing insurance rate covers the subscription, provider visits, and compounded medications. Branded GLP-1 medications are available but billed separately. Some insurance plans may require copays for provider visits; you should verify in-network status and total out-of-pocket costs at enrollment.

Why does Found's month-to-month plan cost more over twelve months than a standard monthly plan?

Found bills every four weeks instead of calendar monthly, which produces thirteen billing cycles per year instead of twelve. At $289 per cycle for semaglutide, this results in $3,757 annually versus $3,468 for twelve calendar-month charges. The billing cadence creates an extra charge that increases the true annual cost.

Can I switch from injectable to oral GLP-1 as a transfer patient with PlexusDx?

Yes. PlexusDx offers injectable semaglutide, injectable tirzepatide, oral semaglutide, oral tirzepatide, and a microdose GLP-1 protocol. Transfer patients can request a format change during a check-in with a Doctor of Pharmacy, subject to provider approval. Found provides injectable formats only.

Which provider is better for long-term maintenance after reaching goal weight?

PlexusDx offers a dedicated microdose GLP-1 protocol at $129/month for maintenance, which costs less than continuing full-dose treatment. Found does not advertise a distinct maintenance protocol; transfer patients would continue on standard dosing. If you anticipate reaching goal weight and want to transition to a lower-cost maintenance option, PlexusDx provides that pathway explicitly.

Sources

• Found pricing and program details, joinFound.com, accessed September 4, 2026
• PlexusDx comparison page for Found, plexusdx.com, accessed September 4, 2026
• PlexusDx pricing and protocol details, plexusdx.com, accessed September 4, 2026

Compounded medication disclosure: Compounded medications are not FDA-approved. FDA does not review compounded drugs before marketing for safety, effectiveness, or quality. A licensed clinician determines whether a prescription is appropriate for an individual patient. PlexusDx works with licensed 503A compounding pharmacies.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.